Amphenol (APH)
(Delayed Data from NYSE)
$120.49 USD
+1.48 (1.24%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $120.50 +0.01 (0.01%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth A Momentum C VGM
Price, Consensus and EPS Surprise
APH 120.49 +1.48(1.24%)
Will APH be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for APH based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for APH
How to Boost Your Portfolio with Top Computer and Technology Stocks Set to Beat Earnings
Why Investors Need to Take Advantage of These 2 Computer and Technology Stocks Now
APH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Amphenol (APH) is an Incredible Growth Stock: 3 Reasons Why
Amphenol's (APH) Q1 Earnings Beat Estimates, Revenues Up Y/Y
Amphenol (APH) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Other News for APH
Decoding Amphenol Corp (APH): A Strategic SWOT Insight
Looking Into Amphenol's Recent Short Interest
Alliance Pharma Sets Preliminary Results Date
Amphenol price target raised by $15 at Truist, here's why
Amphenol price target raised by $3 at BofA, here's why